Postoperative pain following hemorrhoidectomy (surgical procedure to remove hemorrhoids) is a major clinical challenge, often leading to delayed recovery, increased opioid consumption, and reduced patient satisfaction.
Preemptive intravenous ketorolac reduces early postoperative pain and opioid consumption in patients undergoing hemorrhoidectomy.
Postoperative pain following hemorrhoidectomy (surgical procedure to remove hemorrhoids) is a major clinical challenge, often leading to delayed recovery, increased opioid consumption, and reduced patient satisfaction. Preemptive analgesia—given before surgical incision—aims to evade central sensitization and ameliorate early postoperative pain control. This randomized clinical trial investigated the potency of intravenous ketorolac (nonsteroidal anti-inflammatory drugs; NSAIDs) as a preemptive analgesic strategy.
Overall, 61 adults scheduled for hemorrhoidectomy were segregated into two groups:
All patients were given pethidine postoperatively as needed for breakthrough pain. Pain intensity was measured via the verbal rating scale (VRS) at 1 hour and 4 hours after surgery. Total postoperative opioid use was also recorded.
Baseline characteristics, including age and sex, were comparable between the groups (p > 0.05). Postoperative findings revealed that patients in the intervention group experienced markedly lower pain scores at both 1 hour and 4 hours after surgery (p < 0.001). In addition, the requisition for opioid analgesics after surgery was markedly reduced in the intervention group (p = 0.002).
Preemptive administration of intravenous ketorolac successfully reduced early postoperative pain and opioid requirements during hemorrhoidal excision. This approach may help limit opioid-related side effects and improve recovery outcomes. Larger studies with extended follow-up are recommended to confirm these outcomes.
The Surgeon
Evaluating the role of preemptive intravenous ketorolac in preventing post-operative pain in patients undergoing hemorrhoidectomy: A randomized clinical trial
Mohammad Dehbozorgi et al.
Comments (0)